Yale Cancer Center

https://www.yalecancercenter.org/

 

ASCO® 2024
17:22

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "SCLC Treatment Evolution - Debunking Myths, IO Advances, and Long-Term Strategies"

FEATURING Anne Chiang
  • 286 views
  • July 10, 2024
  • 2
03:48

ecancer

ASCO® 2024 Insights: "Results of Preliminary Safety & Efficacy of Belantamab Mafodotin and Elotuzumab in R/R MM"

FEATURING Natalia Neparidze
  • 57 views
  • June 25, 2024
11:13

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Development and Validation of RSClinN+ Tool for HR+/HER2- Node-Positive BC"

FEATURING Lajos Pusztai
  • 176 views
  • June 17, 2024
  • 1
13:29

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Sorafenib Treatment Duration in Desmoid Tumors"

FEATURING Philippos Costa
  • 43 views
  • June 17, 2024
05:56

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NETTER-2 Study - Safety & TTR of [177Lu]Lu-DOTATATE in Pts With Newly Diagnosed Advanced Grade 2 & 3, Well-Differentiated Gastroenteropancreatic NETs"

FEATURING Pamela Kunz
  • 22 views
  • June 12, 2024
09:54

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "1L Systemic Therapy Following Adjuvant IO in RCC"

FEATURING Talal El Zarif
  • 202 views
  • June 11, 2024
14:01

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunotherapy - Pre-op, Post-op or No-op? NADINA Trial Discussion"

FEATURING Harriet Kluger
  • 102 views
  • June 10, 2024
  • 1
23:31

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Harnessing the Immune System in RCC - Current and Novel IO Approaches"

FEATURING David Braun
  • 171 views
  • June 7, 2024
05:28

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC - Initial Results of a Phase 1/2 Study"

FEATURING Daniel Petrylak
  • 36 views
  • June 6, 2024
13:33

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Impact of Exposure on Outcomes With Enfortumab Vedotin in Patients With Locally Advanced or Metastatic Urothelial Cancer"

FEATURING Daniel Petrylak
  • 141 views
  • June 6, 2024